BR9908723A - Compound, use of same, pharmaceutical composition, processes to modulate the activity of one or more ptpases or other molecules with phosphotyrosine recognition unit (s) in an individual in need of this control, to isolate a protein, to copulate a fluorescent molecule or radiation to a compound, to detect protein tyrosine phosphatase or other molecules, to quantify the amount of protein tyrosine phosphatase or other molecules, and, to determine the function of a given protein tyrosine phosphatase or protein tyrosine phosphatase group or said molecules . - Google Patents

Compound, use of same, pharmaceutical composition, processes to modulate the activity of one or more ptpases or other molecules with phosphotyrosine recognition unit (s) in an individual in need of this control, to isolate a protein, to copulate a fluorescent molecule or radiation to a compound, to detect protein tyrosine phosphatase or other molecules, to quantify the amount of protein tyrosine phosphatase or other molecules, and, to determine the function of a given protein tyrosine phosphatase or protein tyrosine phosphatase group or said molecules .

Info

Publication number
BR9908723A
BR9908723A BR9908723-5A BR9908723A BR9908723A BR 9908723 A BR9908723 A BR 9908723A BR 9908723 A BR9908723 A BR 9908723A BR 9908723 A BR9908723 A BR 9908723A
Authority
BR
Brazil
Prior art keywords
molecules
tyrosine phosphatase
protein tyrosine
protein
compound
Prior art date
Application number
BR9908723-5A
Other languages
Portuguese (pt)
Inventor
Henrik Sune Andersen
Josef Vagner
Claus Bekker Jeppesen
Niels Peter Hundahl M Ller
Sven Branner
Lone Jeppesen
Ole Hvilsted Olsen
Lars Fogh Iversen
Daniel Dale Holsworth
Frank Urban Axe
Yu Ge
Todd Kevin Jones
William Charles Ripka
Roy Teruyuki Uyeda
Jing Su
Farid Bakir
Luke Milburn Judge
Original Assignee
Novo Nordisk As
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Ontogen Corp filed Critical Novo Nordisk As
Priority claimed from PCT/DK1999/000126 external-priority patent/WO1999046237A1/en
Publication of BR9908723A publication Critical patent/BR9908723A/en

Links

Abstract

"COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA, PROCESSOS PARA MODULAR A ATIVIDADE DE UMA OU MAIS PTPASES OU OUTRAS MOLéCULAS COM UNIDADE(S) DE RECONHECIMENTO DE FOSFOTIROSINA EM UM INDIVìDUO EM NECESSIDADE DESTE CONTROLE, PARA ISOLAR UMA PROTEìNA, PARA COPULAR UMA MOLéCULA FLUORESCENTE OU RADIOATIVA A UM COMPOSTO, PARA DETECTAR PROTEìNA-TIROSINA FOSFATASE OU OUTRAS MOLéCULAS, PARA QUANTIFICAR A QUANTIDADE DE PROTEìNA-TIROSINA FOSFATASES OU OUTRAS MOLéCULAS, E, PARA DETERMINAR A FUNçãO DE UMA DADA PROTEìNA-TIROSINA FOSFATASE OU GRUPO DE PROTEìNA-TIROSINA FOSFATASES OU REFERIDAS MOLéCULAS". A presente invenção provê novos compostos, novas composições, processos de seu uso e processos de sua fabricação, onde os compostos são inibidores farmacologicamente utilizáveis de proteína tirosina fosfatases (PTPases, PTPs) como PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTPa, PTPe, PTPm, PTP d, PTPs, PTPx, PTPb, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR e HePTP. Estes compostos são indicados no controle ou tratamento de uma ampla faixa de doenças como doenças autoimunes, inflamação aguda e crónica, osteoporose, várias formas de câncer e doenças malignas, e diabete tipo I e diabete tipo II."COMPOUND, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, PROCESSES TO MODULATE THE ACTIVITY OF ONE OR MORE PTPASES OR OTHER MOLECULES WITH PHOSPHOTYROSOSINE RECOGNITION UNIT (S) IN AN INDIVIDUAL IN NEED OF THIS CONTROL, TO ISOLATE A PROTEIN, TO PROVIDE A PROTECTED PROTEIN. OR RADIOACTIVE TO A COMPOUND, TO DETECT PROTEIN-TYROSINE PHOSPHATASE OR OTHER MOLECULES, TO QUANTIFY THE AMOUNT OF PROTEIN-TYROSINE PHOSPHATASE OR OTHER MOLECULES, AND TO DETERMINE THE FUNCTION OF A DATA PROTEIN-TINE PROTECTION REFERRED TO MOLECULES ". The present invention provides new compounds, new compositions, processes of their use and processes of their manufacture, where the compounds are pharmacologically usable inhibitors of protein tyrosine phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP -2, PTPa, PTPe, PTPm, PTP d, PTPs, PTPx, PTPb, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR and HePTP. These compounds are indicated for the control or treatment of a wide range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignancies, and type I diabetes and type II diabetes.

BR9908723-5A 1998-03-12 1999-03-12 Compound, use of same, pharmaceutical composition, processes to modulate the activity of one or more ptpases or other molecules with phosphotyrosine recognition unit (s) in an individual in need of this control, to isolate a protein, to copulate a fluorescent molecule or radiation to a compound, to detect protein tyrosine phosphatase or other molecules, to quantify the amount of protein tyrosine phosphatase or other molecules, and, to determine the function of a given protein tyrosine phosphatase or protein tyrosine phosphatase group or said molecules . BR9908723A (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
DK34498 1998-03-12
DK35098 1998-03-12
DK34698 1998-03-12
DK34898 1998-03-12
DK34798 1998-03-12
DK34598 1998-03-12
DK34398 1998-03-12
DK34298 1998-03-12
DK47398 1998-04-03
DK48098 1998-04-03
DK47298 1998-04-03
PCT/DK1999/000126 WO1999046237A1 (en) 1998-03-12 1999-03-12 Modulators of protein tyrosine phosphatases

Publications (1)

Publication Number Publication Date
BR9908723A true BR9908723A (en) 2000-11-21

Family

ID=27581527

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908723-5A BR9908723A (en) 1998-03-12 1999-03-12 Compound, use of same, pharmaceutical composition, processes to modulate the activity of one or more ptpases or other molecules with phosphotyrosine recognition unit (s) in an individual in need of this control, to isolate a protein, to copulate a fluorescent molecule or radiation to a compound, to detect protein tyrosine phosphatase or other molecules, to quantify the amount of protein tyrosine phosphatase or other molecules, and, to determine the function of a given protein tyrosine phosphatase or protein tyrosine phosphatase group or said molecules .

Country Status (1)

Country Link
BR (1) BR9908723A (en)

Similar Documents

Publication Publication Date Title
Lee et al. Ceramide inactivates cellular protein kinase Cα
Benhamou et al. High-affinity IgE receptor-mediated stimulation of rat basophilic leukemia (RBL-2H3) cells induces early and late protein-tyrosine phosphorylations.
Gomathi et al. Regulation of Runx2 by post-translational modifications in osteoblast differentiation
Kleinsmith Phosphorylation of non‐histone proteins in the regulation of chromosome structure and function
Mhawech 14-3-3 proteins—an update
Taylor et al. Biochemical markers of bone turnover for the clinical assessment of bone metabolism
Miller et al. Inhibition of phosphatidylinositol 3-kinase activity blocks depolarization-and insulin-like growth factor I-mediated survival of cerebellar granule cells
Kanety et al. Tumor Necrosis Factor α-induced Phosphorylation of Insulin Receptor Substrate-1 (IRS-1): POSSIBLE MECHANISM FOR SUPPRESSION OF INSULIN-STIMULATED TYROSINE PHOSPHORYLATION OF IRS-1 (∗)
Denu et al. Protein tyrosine phosphatases: mechanisms of catalysis and regulation
Liu et al. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody
Shao et al. Activation of PKCα downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells
Khurana et al. Brush Border Phosphatidylinositol 3-Kinase Mediates Epidermal Growth Factor Stimulation of Intestinal NaCl Absorption and Na+/H+ Exchange (∗)
Shimizu et al. Lamin B phosphorylation by protein kinase Cα and proteolysis during apoptosis in human leukemia HL60 cells
Vetter et al. Assessment of protein-tyrosine phosphatase 1B substrate specificity using “inverse alanine scanning”
Kim et al. Gangliosides inhibit phospholipid‐sensitive Ca2+‐dependent kinase phosphorylation of rat myelin basic proteins
Horne et al. Differential phosphorylation of multiple sites in protein 4.1 and protein 4.9 by phorbol ester-activated and cyclic AMP-dependent protein kinases.
Fluck et al. Skeletal muscle Ca2+-independent kinase activity increases during either hypertrophy or running
Galasinski et al. Global regulation of post-translational modifications on core histones
Price et al. Effects of regulatory subunits on the kinetics of protein phosphatase 2A
Yin et al. Casein kinase II phosphorylates lens connexin 45.6 and is involved in its degradation
Kishimoto et al. Activation of glycogen phosphorylase kinase by a calcium-activated, cyclic nucleotide-independent protein kinase system.
Clulow et al. Competition-based, quantitative chemical proteomics in breast cancer cells identifies new target profiles for sulforaphane
Kratzmeier et al. Rapid dephosphorylation of H1 histones after apoptosis induction
Webb et al. 1-(N-alkylamino)-11-(N-ethylamino)-4, 8-diazaundecanes: simple synthetic polyamine analogues that differentially alter tubulin polymerization
Scotto et al. Cysteine oxidation in the mitogenic S100B protein leads to changes in phosphorylation by catalytic CKII-α subunit

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTA A 5O, 6O, 7O E 8O ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.